Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
NCT ID: NCT04517175
Last Updated: 2020-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2020-09-01
2025-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Factors for All Types of Cancer Combined
NCT00704587
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma
NCT01358617
Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
NCT01366170
Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia
NCT02330718
Biomarkers in Samples From Young Patients With Neuroblastoma
NCT01358604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myelodysplastic syndrome (MDS) patients
MDS patients will be divided according to prognostic parameters in sub-cohorts.
Flow cytometry
Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
Acute myeloid Leukemia (AML) patients
AML patients will be divided according to prognostic parameters in sub-cohorts.
Flow cytometry
Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
Myelodysplastic syndrome/neoplasm (MDS/MPN) patients
MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.
Flow cytometry
Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flow cytometry
Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zuyderland Medisch Centrum
OTHER
Maastricht University Medical Center
OTHER
Maastricht University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefan Mestrum
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Nies KPH, Kraaijvanger R, Lindelauf KHK, Drent RJMR, Rutten RMJ, Ramaekers FCS, Leers MPG. Determination of the proliferative fractions in differentiating hematopoietic cell lineages of normal bone marrow. Cytometry A. 2018 Nov;93(11):1097-1105. doi: 10.1002/cyto.a.23564. Epub 2018 Sep 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-1345
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.